PMID: 8946280Nov 1, 1996Paper

P-glycoprotein-mediated multidrug resistance and lymphokine-activated killer cell susceptibility in ovarian carcinoma

Journal of Clinical Immunology
B SavasH F Pross

Abstract

The sensitivity of tumor cells to lysis by natural killer (NK) and interleukin-2 (IL-2)-activated killer (LAK) cells was studied in three ovarian carcinoma cell lines (2780.9S, SKOV-3, and CHOAUXB1), four multidrug-resistant (MDR) variants, and a melphalan-resistant line. The antitumor activity of LAK cells was evaluated both by 51Cr release and by conjugate formation assays. Four of four P-glycoprotein-positive (P-gp+) MDR ovarian carcinoma cell line variants were lysed by human LAK cells to a greater extent than were their drug-sensitive counterparts. In contrast, a melphalan-resistant ovarian carcinoma cell line that does not overexpress P-gp (P-gp-) did not exhibit an increased susceptibility to LAK cells relative to its parental cell line. Two of the four P-gp+ MDR ovarian carcinoma cell line variants were tested for human NK cell susceptibility and this was found to be unchanged or decreased. The P-gp+ MDR ovarian carcinoma cell line 2780.AD645 showed a higher frequency of tumor cell binding to LAK cells than did the drug-sensitive parental line. A monoclonal antibody (mAb) against a cell surface epitope of P-gp, MRK16, used at 1 microgram/ml, enhanced the LAK susceptibility of P-gp+ MDR ovarian carcinoma cell lines. Howe...Continue Reading

References

Jul 7, 1992·Biochimica Et Biophysica Acta·D Nielsen, T Skovsgaard
Jan 1, 1990·Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology·E W AdesJ Pruckler
Dec 1, 1989·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·P F JurankaV Ling
Jan 1, 1989·Seminars in Surgical Oncology·A E Chang, S A Rosenberg
Oct 15, 1989·International Journal of Cancer. Journal International Du Cancer·J Van DijkS O Warnaar
Feb 18, 1988·Biochimica Et Biophysica Acta·A L ArsenaultN Kartner
Sep 1, 1988·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·G WoodsA Ochi
Jun 1, 1988·Journal of Leukocyte Biology·R R PadmanabhanD M Lopez
Oct 15, 1988·International Journal of Cancer. Journal International Du Cancer·C Gambacorti-PasseriniG Parmiani
Jul 15, 1987·International Journal of Cancer. Journal International Du Cancer·P AllavenaA Mantovani
Feb 1, 1974·Journal of Cellular Physiology·V Ling, L H Thompson
Feb 20, 1967·JAMA : the Journal of the American Medical Association·G E MooreH A Franklin
Jan 1, 1981·International Archives of Allergy and Applied Immunology·H F ProssM G Baines
Sep 1, 1994·Current Opinion in Oncology·W H Gotlieb, J S Berek
Jan 1, 1993·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A RedmondM Clynes
Jan 1, 1993·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·M FerdeghiniR Bianchi
Aug 1, 1993·British Journal of Cancer·J A GreenA H Clark
Nov 15, 1995·Cancer·C D RunowiczG L Goldberg
Feb 1, 1964·Lancet·J V PULVERTAFT

❮ Previous
Next ❯

Citations

Dec 31, 1997·American Journal of Reproductive Immunology : AJRI·C M YasharC Gerçel-Taylor

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.